Challenges of glycosylation analysis and control: An integrated approach to producing optimal and consistent therapeutic drugs

Drug Discovery Today

Volumn 21, Issue 5, 2016, Pages 740-765

  Zhang, Peiqing ^a,b   Woen, Susanto ^a   Wang, Tianhua ^a   Liau, Brian ^a   Zhao, Sophie ^a   Chen, Chen ^a   Yang, Yuansheng ^a   Song, Zhiwei ^a,b   Wormald, Mark R ^c   Yu, Chuanfei ^d   Rudd, Pauline M ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CETUXIMAB; CHORIONIC GONADOTROPIN; FOLLITROPIN; GAMMA INTERFERON; GLYCOPROTEIN; LECTIN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANTIGEN BINDING; BIOPROCESS; CAPILLARY ELECTROPHORESIS; CELL CULTURE; CELL LINE; DATA PROCESSING; DRUG PURIFICATION; EXPRESSION VECTOR; GENE EXPRESSION SYSTEM; GLYCOSYLATION; HOST CELL; HUMAN; IMMUNITY; INFORMATION SCIENCE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; REVIEW; ANIMAL; DRUG DEVELOPMENT; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; DRUG DISCOVERY; GLYCOPROTEINS; GLYCOSYLATION; HUMANS;

EID: 84957922718     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.01.006     Document Type: Review

References (259)

1. R. Apweiler, and et al. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database Biochim. Biophys. Acta 1473 1999 4 8
2. A.J. Parodi Protein glucosylation and its role in protein folding Annu. Rev. Biochem. 69 2000 69 93
3. K.W. Moremen, and et al. Vertebrate protein glycosylation: diversity, synthesis and function Nat. Rev. Mol. Cell Biol. 13 2012 448 462
4. P.A. Wearsch, and et al. Essential glycan-dependent interactions optimize MHC class I peptide loading Proc. Natl. Acad. Sci. U. S. A. 108 2011 4950 4955
5. J.E. Stencel-Baerenwald, and et al. The sweet spot: defining virus-sialic acid interactions Nat. Rev. Microbiol. 12 2014 739 749
6. J.M. Hayes, and et al. Glycosylation and Fc receptors Curr. Top. Microbiol. Immunol. 382 2014 165 199
7. C.H. Chung, and et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose N. Engl. J. Med. 358 2008 1109 1117
8. A.M. Sinclair Erythropoiesis stimulating agents: approaches to modulate activity Biologics 7 2013 161 174
9. T. Shinkawa, and et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity J. Biol. Chem. 278 2003 3466 3473
10. G. Walsh Biopharmaceutical benchmarks 2014 Nat. Biotechnol. 32 2014 992 1000
11. D.M. Ecker, and et al. The therapeutic monoclonal antibody market MAbs 7 2015 9 14
12. R.S. Aggarwal What's fueling the biotech engine-2012 to 2013 Nat. Biotechnol. 32 2014 32 39
13. J.N. Arnold, and et al. The impact of glycosylation on the biological function and structure of human immunoglobulins Annu. Rev. Immunol. 25 2007 21 50
14. G. Lauc, and et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers PLoS Genet. 9 2013 e1003225
15. R. Saldova, and et al. 5-AZA-2′-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer Epigenetics 6 2011 1362 1372
16. P. Hossler, and et al. Optimal and consistent protein glycosylation in mammalian cell culture Glycobiology 19 2009 936 949
17. M. Daeron Fc receptors as adaptive immunoreceptors Curr. Top. Microbiol. Immunol. 382 2014 131 164
18. C.P. Milstein, and E.V. Deverson Primary structure of ° light chain from a human myeloma protein Eur. J. Biochem. 49 1974 377 391
19. F. Arakawa, and et al. Construction and expression of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen Hybridoma 12 1993 365 379
20. K. Kusakabe, and et al. Accumulation enhancement of human monoclonal antibody HB4C5 to lung tumor xenografts by N-deglycosylation J. Nucl. Med. 35 1994 289 295
21. S.C. Wallick, and et al. Glycosylation of a VH residue of a monoclonal antibody against alpha (1-6) dextran increases its affinity for antigen J. Exp. Med. 168 1988 1099 1109
22. J.J.L. van Bueren, and et al. Anti-galactose-[alpha]-1,3-galactose IgE from allergic patients does not bind [alpha]-galactosylated glycans on intact therapeutic antibody Fc domains Nat. Biotechnol. 29 2011 574 576
23. S.P. Commins, and T.A.E. Platts-Mills Allergenicity of carbohydrates and their role in anaphylactic events Curr. Allergy Asthma Rep. 10 2010 29 33
24. P.M. Rudd Glycosylation and the immune system Science 291 2001 2370 2376
25. W.H. Yang, and et al. An intrinsic mechanism of secreted protein aging and turnover Proc. Natl. Acad. Sci. U. S. A. 112 2015 13657 13662
26. X. Dong, and et al. Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells J. Immunol. 163 1999 5427 5434
27. R. Malhotra, and et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein Nat. Med. 1 1995 237 243
28. A.M. Goetze, and et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans Glycobiology 21 2011 949 959
29. T. Ishino, and et al. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics J. Biol. Chem. 288 2013 16529 16537
30. T. Kibe, and et al. Glycosylation and placental transport of immunoglobulin G J. Clin. Biochem. Nutr. 21 1996 57 63
31. S. Krapp, and et al. Structural analysis of human IgG-Fc glycoforms reveals correlation between glycosylation and structural integrity J. Mol. Biol. 325 2003 979 989
32. Y. Mimura, and et al. Role of oligosaccharide residues of IgG1-Fc in Fc RIIb binding J. Biol. Chem. 276 2001 45539 45547
33. C. Ferrara, and et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc(RIII and antibodies lacking core fucose Proc. Natl. Acad. Sci. U. S. A. 108 2011 12669 12674
34. M.R. van Schravendijk, and R.A. Dwek The use of protein A and concanavalin A to examine the possible role of the carbohydrate of IgG in the binding of Clq Mol. Immunol. 18 1981 1079 1085
35. D.R. Burton, and et al. The Clq receptor site on immunoglobulin G Nature 288 1980 338 344
36. Y. Mimura, and et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms Mol. Immunol. 37 2000 697 706
37. R.L. Shields, and et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc(RIII and antibody-dependent cellular toxicity J. Biol. Chem. 277 2002 26733 26740
38. A. Pincetic, and et al. Type I and type II Fc receptors regulate innate and adaptive immunity Nat. Immunol. 15 2014 707 716
39. E.A. Padlan Anatomy of the antibody molecule Mol. Immunol. 31 1994 169 217
40. N. Washburn, and et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity Proc. Natl. Acad. Sci. U. S. A. 112 2015 E1297 E1306
41. C. Yu, and et al. At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody Sci. Rep. 7 2016 10.1038/srep20029 (article no. 20029)
42. J-M. Yang, and et al. Investigation of the correlation between charge and glycosylation of IgG1 variants by liquid chromatography-mass spectrometry Anal. Biochem. 448 2014 82 91
43. Y. Kaneko, and et al. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science 313 2006 670 673
44. A. Samuelsson, and et al. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Science 291 2001 484 486
45. I.K. Campbell, and et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils J. Immunol. 192 2014 5031 5038
46. A.C. Issekutz, and et al. Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells Clin. Immunol. 160 2015 123 132
47. S.Q. Nagelkerke, and et al. Inhibition of Fc(R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc(RIIb in human macrophages Blood 124 2014 3709 3718
48. R.M. Anthony, and et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway Nature 475 2011 110 113
49. J. Bayry, and et al. Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease J. Rheumatol. 39 2012 450 451
50. A. Kessel, and et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function J. Immunol. 179 2007 5571 5575
51. C. Ramakrishna, and E.M. Cantin Fc-sialylated IgGs in intravenous immunoglobulins are not responsible for induction of regulatory T cells J. Allergy Clin. Immunol. 134 2014 1469
52. D. Zhu, and et al. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma Blood 99 2002 2562 2568
53. H.U. Scherer, and et al. Immunoglobulin 1 (IgG1) Fc-glycosylation profiling of anti-citrullinated peptide antibodies from human serum Proteomics Clin. Appl. 3 2009 106 115
54. E.A. Kabat, and et al. Sequences of Proteins of Immunological Interest 1992 DIANE Publishing
55. A. Wright, and et al. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure EMBO J. 10 1991 2717
56. M. Jacquemin Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody Haemophilia 16 2009 16 19
57. R. Song, and et al. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity Nat. Biotechnol. 31 2013 1047 1052
58. Z. Sabouri, and et al. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity Proc. Natl. Acad. Sci. U. S. A. 111 2014 E2567 E2575
59. N. Kinoshita, and et al. Glycosylation at the Fab portion of myeloma immunoglobulin G and increased fucosylated biantennary sugar chains: structural analysis by high-performance liquid chromatography and antibody-lectin enzyme immunoassay using Lens culinaris agglutinin Cancer Res. 51 1991 5888 5892
60. A. Youings, and et al. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients Biochem. J. 314 1996 621 630
61. C.M. Radcliffe, and et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor J. Biol. Chem. 282 2007 7405 7415
62. V. Coelho, and et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins Proc. Natl. Acad. Sci. U. S. A. 107 2010 18587 18592
63. P. Tangvoranuntakul, and et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid Proc. Natl. Acad. Sci. U. S. A. 100 2003 12045 12050
64. D. Ghaderi, and et al. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins Nat. Biotechnol. 28 2010 863 867
65. A. Noguchi, and et al. Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells J. Biochem. 117 1995 59 62
66. C.J. Bosques, and et al. Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins Nat. Biotechnol. 28 2010 1153 1156
67. M. Hanganutziu Hémagglutinines hétérogénétiques après injection de sérum de cheval CR Séances Soc. Biol. 91 1924 1457 1459 (in French)
68. D.H. Deicher Über die erzeugung heterospezifischer hämagglutinine durch injektion artfremden serums Zeitschrift Hygiene Infektionskrankheiten 106 1926 561 579 (in German)
69. B. Pirofsky, and et al. Foreign serum heterophile antibodies in patients receiving antithymocyte antisera Blood 42 1973 385 393
70. H. Higashi, and et al. Antigen of serum sickness type of heterophile antibodies in human sera: indentification as gangliosides with N-glycolylneuraminic acid Biochem. Biophys. Res. Commun. 79 1977 388 395
71. R.M. Anthony, and et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc Science 320 2008 373 376
72. J. Stadlmann, and et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation Proteomics 9 2009 4143 4153
73. J. Stadlmann, and et al. Analytical and functional aspects of antibody sialylation J. Clin. Immunol. 30 2010 15 19
74. B.H. O'Neil, and et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history J. Clin. Oncol. 25 2007 3644 3648
75. N. Casadevall, and et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin N. Engl. J. Med. 346 2002 469 475
76. S.P. Commins, and et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1,3-galactose J. Allergy Clin. Immunol. 123 2009 426 433 e422
77. S.P. Commins, and et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose J. Allergy Clin. Immunol. 127 2011 1286 1293 e1286
78. World Health Organization Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) 2009 Available at: http://apps.who.int/medicinedocs/documents/s19941en/s19941en.pdf
79. European Medicines Agency Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Active Substance: Non-clinical and Clinical Issues 2013 Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003920.pdf
80. E.K. Read, and et al. Industry and regulatory experience of the glycosylation of monoclonal antibodies Biotechnol. Appl. Biochem. 58 2011 213 219
81. M. Schiestl, and et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals Nat. Biotechnol. 29 2011 310 312
82. M. Schiestl A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products Biologicals 39 2011 297 299
83. U.S. Department of Health and Human Services Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product 2012 Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf
84. P.H.C. Van Berkel, and et al. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG Biotechnol. Prog. 25 2009 244 251
85. J. Chusainow, and et al. A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer? Biotechnol. Bioeng. 102 2009 1182 1196
86. Y. Rouiller, and et al. Modulation of mAb quality attributes using microliter scale fed-batch cultures Biotechnol. Prog. 30 2014 571 583
87. R. Bareither, and et al. Automated disposable small scale reactor for high throughput bioprocess development: a proof of concept study Biotechnol. Bioeng. 110 2013 3126 3138
88. T.A. Barrett, and et al. Microwell engineering characterization for mammalian cell culture process development Biotechnol. Bioeng. 105 2010 260 275
89. A. Eon-Duval, and et al. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach Biotechnol. Prog. 28 2012 608 622
90. M.J. Gramer Product quality considerations for mammalian cell culture process development and manufacturing W. Zhou, A. Kantardjieff, Mammalian Cell Cultures for Biologics Manufacturing Vol. 139 2014 Springer-Verlag Berlin 123 166
91. B. Kelley Industrialization of mAb production technology: the bioprocessing industry at a crossroads MAbs 1 2009 443 452
92. S.C.L. Ho, and et al. Generation of monoclonal antibody-producing mammalian cell lines Pharm. Bioprocess. 1 2013 71 87
93. M. Wadhwa, and R. Thorpe European perspective on biosimilars Bioanalysis 5 2013 521 524
94. S-C. Chow, and et al. Comments on the FDA draft guidance on biosimilar products Statistics Med. 32 2013 364 369
95. P. Hossler Protein glycosylation control in mammalian cell culture: past precedents and contemporary prospects Adv. Biochem. Eng. Biotechnol. 127 2012 187 219
96. S.L. Davies, and et al. Functional heterogeneity and heritability in CHO cell populations Biotechnol. Bioeng. 110 2013 260 274
97. S.C.L. Ho, and et al. IRES-mediated Tricistronic vectors for enhancing generation of high monoclonal antibody expressing CHO cell lines J. Biotechnol. 157 2012 130 139
98. S.C.L. Ho, and et al. Control of IgG LC:HC ratio in stably transfected CHO cells and study of the impact on expression, aggregation, glycosylation and conformational stability J. Biotechnol. 165 2013 157 166
99. F. Li, and et al. Cell culture processes for monoclonal antibody production MAbs 2 2010 466 479
100. G.M. Pastores Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease BioDrugs 24 2010 41 47
101. M. Thomann, and et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity PLoS One 10 2015 e0134949
102. Y. Mimura, and et al. Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines J. Immunol. Methods 2015 10.1016/j.jim.2015.11.009
103. S.K. Patnaik, and P. Stanley Lectin-resistant CHO glycosylation mutants Methods Enzymol. 416 2006 159 182
104. P. Zhang, and et al. CHO glycosylation mutants as potential host cells to produce therapeutic proteins with enhanced efficacy Adv. Biochem. Eng. Biotechnol. 131 2013 63 87
105. P. Zhang, and et al. Identification of functional elements of the GDP-fucose transporter SLC35C1 using a novel Chinese hamster ovary mutant Glycobiology 22 2012 897 911
106. C. Steentoft, and et al. Precision genome editing: a small revolution for glycobiology Glycobiology 24 2014 663 680
107. W.C. Wang, and R.D. Cummings The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues J. Biol. Chem. 263 1988 4576 4585
108. R.N. Knibbs, and et al. Characterization of the carbohydrate binding specificity of the leukoagglutinating lectin from Maackia amurensis. Comparison with other sialic acid-specific lectins J. Biol. Chem. 266 1991 83 88
109. D. Ghaderi, and et al. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation Biotechnol. Genet. Eng. Rev. 28 2012 147 175
110. S.F. Lim, and et al. The Golgi CMP-sialic acid transporter: a new CHO mutant provides functional insights Glycobiology 18 2008 851 860
111. J.S. Goh, and et al. RCA-I-resistant CHO mutant cells have dysfunctional GnT I and expression of normal GnT I in these mutants enhances sialylation of recombinant erythropoietin Metab. Eng. 12 2010 360 368
112. J.S. Goh, and et al. Highly sialylated recombinant human erythropoietin production in large-scale perfusion bioreactor utilizing CHO-gmt4 (JW152) with restored GnT I function Biotechnol. J. 9 2014 100 109
113. D.J. Segal, and et al. Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5′-GNN-3′ DNA target sequences Proc. Natl. Acad. Sci. U. S. A. 96 1999 2758 2763
114. B. Dreier, and et al. Insights into the molecular recognition of the 5′-GNN-3′ family of DNA sequences by zinc finger domains J. Mol. Biol. 303 2000 489 502
115. Q. Liu, and et al. Validated zinc finger protein designs for all 16 GNN DNA triplet targets J. Biol. Chem. 277 2002 3850 3856
116. J.D. Sander, and et al. Zinc finger targeter (ZiFiT): an engineered zinc finger/target site design tool Nucleic Acids Res. 35 2007 W599 W605
117. T. Cermak, and et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting Nucleic Acids Res. 39 2011 e82
118. J.C. Miller, and et al. A TALE nuclease architecture for efficient genome editing Nat. Biotechnol. 29 2011 143 148
119. J. Boch, and et al. Breaking the code of DNA binding specificity of TAL-type III effectors Science 326 2009 1509 1512
120. M.J. Moscou, and A.J. Bogdanove A simple cipher governs DNA recognition by TAL effectors Science 326 2009 1501
121. N.E. Sanjana, and et al. A transcription activator-like effector toolbox for genome engineering Nat. Protocols 7 2012 171 192
122. D. Reyon, and et al. FLASH assembly of TALENs for high-throughput genome editing Nat. Biotechnol. 30 2012 460 465
123. L. Cong, and et al. Multiplex genome engineering using CRISPR/Cas systems Science 339 2013 819 823
124. P. Mali, and et al. RNA-guided human genome engineering via Cas9 Science 339 2013 823 826
125. L.M. Grav, and et al. One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment Biotechnol. J. 10 2015 1446 1456
126. T.G. Montague, and et al. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing Nucleic Acids Res. 42 2014 W401 W407
127. X. Wu, and et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells Nat. Biotechnol. 32 2014 670 676
128. C. Kuscu, and et al. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease Nat. Biotechnol. 32 2014 677 683
129. P.M.J. Jedrzejewski, and et al. Applying quality by design to glycoprotein therapeutics: experimental and computational efforts of process control Pharm. Bioprocess. 1 2013 51 69
130. A.S. Rathore Roadmap for implementation of quality by design (QbD) for biotechnology products Trends Biotechnol. 27 2009 546 553
131. I.J. del Val, and et al. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns Biotechnol. Prog. 26 2010 1505 1527
132. J. Hodoniczky, and et al. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro Biotechnol. Prog. 21 2005 1644 1652
133. R.L. Shields, and et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity J. Biol. Chem. 277 2002 26733 26740
134. D. Fernandes High-Throughput Multi-Product Liquid Chromatography for Characterization of Monoclonal Antibodies 2011 BioPharm International
135. Prozyme® GlykoPrep™ Guidebook. Available at: http://www.prozyme.com/documents/TNGP100.pdf.
136. M. Doherty, and et al. An automated robotic platform for rapid profiling oligosaccharide analysis of monoclonal antibodies directly from cell culture Anal. Biochem. 442 2013 10 18
137. S. Nishimura, and et al. High-throughput protein glycomics: combined use of chemoselective glycoblotting and MALDI-TOF/TOF mass spectrometry Angew Chem. Int. Ed. Engl. 44 2004 91 96
138. H. Zhang, and et al. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry Nat. Biotechnol. 21 2003 660 666
139. H. Stockmann, and et al. Automated, high-throughput IgG-antibody glycoprofiling platform Anal. Chem. 85 2013 8841 8849
140. D. Reusch, and et al. High-throughput work flow for IgG Fc-glycosylation analysis of biotechnological samples Anal. Biochem. 432 2013 82 89
141. V. Kumar, and et al. Design of experiments applications in bioprocessing: concepts and approach Biotechnol. Prog. 30 2014 86 99
142. M. Alvarez, and et al. On-line characterization of monoclonal antibody variants by liquid chromatography-mass spectrometry operating in a two-dimensional format Anal. Biochem. 419 2011 17 25
143. J. Primack, and et al. A high-throughput microchip-based glycan screening assay for antibody cell culture samples Electrophoresis 32 2011 1129 1132
144. M.A. Bynum, and et al. Characterization of IgG N-glycans employing a microfluidic chip that integrates glycan cleavage, sample purification, LC separation, and MS detection Anal. Chem. 81 2009 8818 8825
145. X. Xu, and et al. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line Nat. Biotechnol. 29 2011 735 741
146. F.J. Krambeck, and et al. A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data Glycobiology 19 2009 1163 1175
147. F.J. Krambeck, and M.J. Betenbaugh A mathematical model of N-linked glycosylation Biotechnol. Bioeng. 92 2005 711 728
148. P. Umana, and J.E. Bailey A mathematical model of N-linked glycoform biosynthesis Biotechnol. Bioeng. 55 1997 890 908
149. P. Hossler, and et al. Systems analysis of N-glycan processing in mammalian cells PLoS One 2 2007 e713
150. P.M. Jedrzejewski, and et al. Towards controlling the glycoform: a model framework linking extracellular metabolites to antibody glycosylation Int. J. Mol. Sci. 15 2014 4492 4522
151. I. Jimenez del Val, and et al. A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus Biotechnol. Prog. 27 2011 1730 1743
152. G. Carta, and A. Jungbauer Protein Chromatography: Process Development and Scale-up 2010 John Wiley & Sons
153. G. El Khoury, and et al. Bespoke affinity ligands for the purification of therapeutic proteins Pharm. Bioprocess 3 2015 139 152
154. H.F. Liu, and et al. Recovery and purification process development for monoclonal antibody production MAbs 2 2010 480 499
155. P. Gagnon, and et al. High productivity purification of immunoglobulin G monoclonal antibodies on starch-coated magnetic nanoparticles by steric exclusion of polyethylene glycol J. Chromatogr. A 1324 2014 171 180
156. P. Gagnon, and et al. Chromatin-mediated depression of fractionation performance on electronegative multimodal chromatography media, its prevention, and ramifications for purification of immunoglobulin G J. Chromatogr. A 1374 2014 145 155
157. P. Gagnon Technology trends in antibody purification J. Chromatogr. A 1221 2012 57 70
158. S. Fanayan, and et al. Using lectins to harvest the plasma/serum glycoproteome Electrophoresis 33 2012 1746 1754
159. R.V. Weatherman, and et al. Specificity of C-glycoside complexation by mannose/glucose specific lectins Biochemistry 35 1996 3619 3624
160. A. Pusztai, and et al. Antinutritive effects of wheat-germ agglutinin and other N-acetylglucosamine-specific lectins Br. J. Nutr. 70 1993 313 321
161. Y. Bourne, and et al. Structural basis for the unusual carbohydrate-binding specificity of jacalin towards galactose and mannose Biochemical J 364 2002 173 180
162. L. Opitz, and et al. Capture of cell culture-derived influenza virus by lectins: strain independent, but host cell dependent J. Virol. Methods 154 2008 61 68
163. L. Opitz, and et al. Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses Vaccine 25 2007 939 947
164. R. dos Santos, and et al. Phenylboronic acid as a multi-modal ligand for the capture of monoclonal antibodies: development and optimization of a washing step J. Chromatogr. A 1355 2014 115 124
165. D. Zanette, and et al. Evaluation of phenylboronate agarose for industrial-scale purification of erythropoietin from mammalian cell cultures J. Biotechnol. 101 2003 275 287
166. Z-A. Lin, and et al. Synthesis of magnetic nanoparticles with immobilized aminophenylboronic acid for selective capture of glycoproteins J. Mater. Chem. 21 2011 518 524
167. W.S. Yeap, and et al. Using detonation nanodiamond for the specific capture of glycoproteins Anal. Chem. 80 2008 4659 4665
168. W. Zhou, and et al. Facile synthesis of aminophenylboronic acid-functionalized magnetic nanoparticles for selective separation of glycopeptides and glycoproteins Chem. Commun. 43 2008 5577 5579
169. R. Ma, and et al. Facile synthesis of boronic acid-functionalized magnetic carbon nanotubes for highly specific enrichment of glycopeptides Nanoscale 6 2014 3150 3156
170. H. Li, and et al. A Wulff-type boronate for boronate affinity capture of cis-diol compounds at medium acidic pH condition Chem. Commun. 47 2011 8169 8171
171. Y. Zhang, and et al. Benzoboroxole-functionalized magnetic core/shell microspheres for highly specific enrichment of glycoproteins under physiological conditions Small 10 2014 1379 1386
172. S. Schumacher, and et al. Label-free detection of enhanced saccharide binding at pH 7.4 to nanoparticulate benzoboroxole based receptor units J. Mol. Recog. 24 2011 953 959
173. D.P. Gamblin, and et al. Glycoprotein synthesis: an update Chem. Rev. 109 2009 131 163
174. A.C. Roque, and et al. Antibodies and genetically engineered related molecules: production and purification Biotechnol. Prog. 20 2004 639 654
175. C. Chen, and et al. Affinity ligands for glycoprotein purification based on the multi-component Ugi reaction J. Chromatogr. B 969 2014 171 180
176. K. Marino, and et al. A systematic approach to protein glycosylation analysis: a path through the maze Nat. Chem. Biol. 6 2010 713 723
177. B.A. Garcia What does the future hold for top down mass spectrometry? J. Am. Soc. Mass Spectrom. 21 2010 193 202
178. S.G. Valeja, and et al. Unit mass baseline resolution for an intact 148 kDa therapeutic monoclonal antibody by Fourier transform ion cyclotron resonance mass spectrometry Anal. Chem. 83 2011 8391 8395
179. Z. Zhang, and et al. Mass spectrometry for structural characterization of therapeutic antibodies Mass Spectrom. Rev. 28 2009 147 176
180. K. Breuker, and et al. Top-down identification and characterization of biomolecules by mass spectrometry J. Am. Soc. Mass Spectrom. 19 2008 1045 1053
181. A. Beck, and et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells J. Chromatogr. B 819 2005 203 218
182. H. Xie, and et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies MAbs 2 2010 379 394
183. Z. Zhang, and B. Shah Characterization of variable regions of monoclonal antibodies by top-down mass spectrometry Anal. Chem. 79 2007 5723 5729
184. P.V. Bondarenko, and et al. Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-Orbitrap mass spectrometer J. Am. Soc. Mass Spectrom. 20 2009 1415 1424
185. A. Beck, and et al. Characterization of therapeutic antibodies and related products Anal. Chem. 85 2013 715 736
186. M.P. Bakovic, and et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides J. Proteome Res. 12 2013 821 831
187. G. Alvarez-Manilla, and et al. Tools for glycoproteomic analysis: size exclusion chromatography facilitates identification of tryptic glycopeptides with N-linked glycosylation sites J. Proteome Res. 5 2006 701 708
188. Y. Wada, and et al. Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics Anal. Chem. 76 2004 6560 6565
189. P. Hagglund, and et al. A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation J. Proteome Res. 3 2004 556 566
190. Y. Takegawa, and et al. Separation of isomeric 2-aminopyridine derivatized N-glycans and N-glycopeptides of human serum immunoglobulin G by using a zwitterionic type of hydrophilic-interaction chromatography J. Chromatogr. A 1113 2006 177 181
191. M. Wuhrer, and et al. Protein glycosylation analysis by liquid chromatography-mass spectrometry J. Chromatogr. B 825 2005 124 133
192. M. Wuhrer, and et al. Protein glycosylation analyzed by normal-phase nano-liquid chromatography - mass spectrometry of glycopeptides Anal. Chem. 77 2005 886 894
193. Z.M. Segu, and Y. Mechref Characterizing protein glycosylation sites through higher-energy C-trap dissociation Rapid Commun. Mass Spectrom. 24 2010 1217 1225
194. M. Wuhrer, and et al. Glycoproteomics based on tandem mass spectrometry of glycopeptides J. Chromatogr. B 849 2007 115 128
195. K. Hakansson, and et al. Electron capture dissociation and infrared multiphoton dissociation MS/MS of an N-glycosylated tryptic peptic to yield complementary sequence information Anal. Chem. 73 2001 4530 4536
196. D.J. Harvey, and et al. Internal residue loss: rearrangements occurring during the fragmentation of carbohydrates derivatized at the reducing terminus Anal. Chem. 74 2002 734 740
197. M. Wuhrer, and et al. Mass spectrometry of proton adducts of fucosylated N-glycans: fucose transfer between antennae gives rise to misleading fragments Rapid Commun. Mass Spectrom. 20 2006 1747 1754
198. J.E. Syka, and et al. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry Proc. Natl. Acad. Sci. U. S. A. 101 2004 9528 9533
199. J.T. Adamson, and K. Hakansson Infrared multiphoton dissociation and electron capture dissociation of high-mannose type glycopeptides J. Proteome Res. 5 2006 493 501
200. K. Hakansson, and et al. Combined electron capture and infrared multiphoton dissociation for multistage MS/MS in a Fourier transform ion cyclotron resonance mass spectrometer Anal. Chem. 75 2003 3256 3262
201. A. Harazono, and et al. Site-specific N-glycosylation analysis of human plasma ceruloplasmin using liquid chromatography with electrospray ionization tandem mass spectrometry Anal. Biochem. 348 2006 259 268
202. A.T. Iavarone, and E.R. Williams Mechanism of charging and supercharging molecules in electrospray ionization J. Am. Chem. Soc. 125 2003 2319 2327
203. L.R. Ruhaak, and et al. Glycan labeling strategies and their use in identification and quantification Anal. Bioanal. Chem. 397 2010 3457 3481
204. J. Zaia Mass spectrometry and the emerging field of glycomics Chem. Biol. 15 2008 881 892
205. M.A. Lauber, and et al. Rapid preparation of released N-glycans for HILIC analysis using a labeling reagent that facilitates sensitive fluorescence and ESI-MS detection Anal. Chem. 87 2015 5401 5409
206. H. Stockmann, and et al. Ultrahigh throughput, ultrafiltration-based N-glycomics platform for ultraperformance liquid chromatography (ULTRA(3)) Anal. Chem. 87 2015 8316 8322
207. D. Guillarme, and et al. New trends in fast and high-resolution liquid chromatography: a critical comparison of existing approaches Anal. Bioanal. Chem. 397 2010 1069 1082
208. L. Novakova, and et al. Advantages of application of UPLC in pharmaceutical analysis Talanta 68 2006 908 918
209. J. Ahn, and et al. Separation of 2-aminobenzamide labeled glycans using hydrophilic interaction chromatography columns packed with 1.7 microm sorbent J. Chromatogr. B 878 2010 403 408
210. M. Pucic, and et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations Mol. Cell. Proteomics 10 2011 10.1074/mcp.M111.010090
211. M.P. Campbell, and et al. GlycoBase and autoGU: resources for interpreting HPLC-glycan data Methods Mol. Biol. 1273 2015 17 28
212. F.J. Duffy, and P.M. Rudd GlycoProfileAssigner: automated structural assignment with error estimation for glycan LC data Bioinformatics 31 2015 2220 2221
213. G. Lauc, and et al. Genomics meets glycomics-the first GWAS study of human N-glycome identifies HNF1alpha as a master regulator of plasma protein fucosylation PLoS Genet. 6 2010 e1001256
214. S. Mittermayr, and et al. Multiplexed analytical glycomics: rapid and confident IgG N-glycan structural elucidation J. Proteome Res. 10 2011 3820 3829
215. D. Reusch, and et al. High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzer MAbs 6 2014 185 196
216. N. Leymarie, and J. Zaia Effective use of mass spectrometry for glycan and glycopeptide structural analysis Anal. Chem. 84 2012 3040 3048
217. D.J. Harvey, and et al. Fragmentation of negative ions from N-linked carbohydrates: part 6. Glycans containing one N-acetylglucosamine in the core Rapid Commun. Mass Spectrom. 28 2014 2008 2018
218. D.J. Harvey, and et al. Travelling wave ion mobility and negative ion fragmentation for the structural determination of N-linked glycans Electrophoresis 34 2013 2368 2378
219. X. Yu, and et al. Detailed glycan structural characterization by electronic excitation dissociation Anal. Chem. 85 2013 10017 10021
220. J.J. Wolff, and et al. Negative electron transfer dissociation of glycosaminoglycans Anal. Chem. 82 2010 3460 3466
221. M.J. Oh, and et al. Analytical platform for glycomic characterization of recombinant erythropoietin biotherapeutics and biosimilars by MS Bioanalysis 5 2013 545 559
222. J. Hofmann, and et al. Estimating collision cross sections of negatively charged N-glycans using traveling wave ion mobility-mass spectrometry Anal. Chem. 86 2014 10789 10795
223. Y. Yamaguchi, and et al. Confident identification of isomeric N-glycan structures by combined ion mobility mass spectrometry and hydrophilic interaction liquid chromatography Rapid Commun. Mass Spectrom. 26 2012 2877 2884
224. P.J. Domann, and et al. Separation-based glycoprofiling approaches using fluorescent labels Proteomics 7 Suppl. 1 2007 70 76
225. C.A. Hayes, and et al. UniCarb-DB: a database resource for glycomic discovery Bioinformatics 27 2011 1343 1344
226. N.V. Artemenko, and et al. Databases and tools in glycobiology Methods Mol. Biol. 899 2012 325 350
227. N.G. Karlsson, and N.H. Packer Glycomic mass spectrometric analysis and data interpretation tools C.-W. von der Lieth, Bioinformatics for Glycobiology and Glycomics 2009 John Wiley & Sons 223 256
228. M.P. Campbell, and et al. Toolboxes for a standardised and systematic study of glycans BMC Bioinformatics 15 Suppl. 1 2014 S9
229. Y. Wada, and et al. Comparison of the methods for profiling glycoprotein glycans-HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study Glycobiology 17 2007 411 422
230. C.W. von der Lieth, and et al. The role of informatics in glycobiology research with special emphasis on automatic interpretation of MS spectra Biochim. Biophys. Acta 1760 2006 568 577
231. C.A. Cooper, and et al. GlycoMod - a software tool for determining glycosylation compositions from mass spectrometric data Proteomics 1 2001 340 349
232. H.J. Joshi, and et al. Development of a mass fingerprinting tool for automated interpretation of oligosaccharide fragmentation data Proteomics 4 2004 1650 1664
233. K.K. Lohmann, and C.W. von der Lieth GLYCO-FRAGMENT: a web tool to support the interpretation of mass spectra of complex carbohydrates Proteomics 3 2003 2028 2035
234. K.K. Lohmann, and C.W. von der Lieth GlycoFragment and GlycoSearchMS: web tools to support the interpretation of mass spectra of complex carbohydrates Nucleic Acids Res. 32 2004 W261 W266
235. E.P. Go, and et al. GlycoPep DB: a tool for glycopeptide analysis using a Smart Search Anal. Chem. 79 2007 1708 1713
236. N. Deshpande, and et al. GlycoSpectrumScan: fishing glycopeptides from MS spectra of protease digests of human colostrum sIgA J. Proteome Res. 9 2010 1063 1075
237. D. Goldberg, and et al. Automatic annotation of matrix-assisted laser desorption/ionization N-glycan spectra Proteomics 5 2005 865 875
238. D. Goldberg, and et al. Automatic determination of O-glycan structure from fragmentation spectra J. Proteome Res. 5 2006 1429 1434
239. D. Goldberg, and et al. Automated N-glycopeptide identification using a combination of single- and tandem-MS J. Proteome Res. 6 2007 3995 4005
240. J. Irungu, and et al. Simplification of mass spectral analysis of acidic glycopeptides using GlycoPep ID Anal. Chem. 79 2007 3065 3074
241. C.L. Woodin, and et al. GlycoPep grader: a web-based utility for assigning the composition of N-linked glycopeptides Anal. Chem. 84 2012 4821 4829
242. K.B. Chandler, and et al. Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search J. Proteome Res. 12 2013 3652 3666
243. Z. Zhu, and et al. GlycoPep Detector: a tool for assigning mass spectrometry data of N-linked glycopeptides on the basis of their electron transfer dissociation spectra Anal. Chem. 85 2013 5023 5032
244. L. He, and et al. GlycoMaster DB: software to assist the automated identification of N-linked glycopeptides by tandem mass spectrometry J. Proteome Res. 13 2014 3881 3895
245. S.P. Gaucher, and et al. STAT: a saccharide topology analysis tool used in combination with tandem mass spectrometry Anal. Chem. 72 2000 2331 2336
246. H. Tang, and et al. Automated interpretation of MS/MS spectra of oligosaccharides Bioinformatics 21 Suppl. 1 2005 431 439
247. K. Maass, and et al. Glyco-peakfinder - de novo composition analysis of glycoconjugates Proteomics 7 2007 4435 4444
248. A.V. Nairn, and et al. Regulation of glycan structures in animal tissues: transcript profiling of glycan-related genes J. Biol. Chem. 283 2008 17298 17313
249. P. Hossler, and et al. GlycoVis: visualizing glycan distribution in the protein N-glycosylation pathway in mammalian cells Biotechnol. Bioeng. 95 2006 946 960
250. T. Nakahara, and et al. Glycoconjugate Data Bank: structures - an annotated glycan structure database and N-glycan primary structure verification service Nucleic Acids Res. 36 2008 D368 D371
251. K.F. Aoki-kinoshita, and M. Kanehisa Bioinformatics analysis of glycan structures from a genomic perspective T. Luetteke, M. Frank, Bioinformatics for Glycobiology and Glycomics 2009 John Wiley & Sons 125 141
252. K. Hashimoto, and et al. KEGG as a glycome informatics resource Glycobiology 16 2006 63 70R
253. M. Kanehisa, and et al. From genomics to chemical genomics: new developments in KEGG Nucleic Acids Res. 34 2006 D354 D357
254. S. Nimmagadda, and et al. GlycoVault: a bioinformatics infrastructure for glycan pathway visualization, analysis and modeling. Information Technology: New Generations Fifth International Conference 2008 692 697
255. A. Ceroni, and et al. The GlycanBuilder: a fast, intuitive and flexible software tool for building and displaying glycan structures Source Code Biol. Med. 2 2007 3
256. K.F. Aoki-Kinoshita Analyzing glycan structure synthesis with the Glycan Pathway Predictor (GPP) tool Methods Mol. Biol. 1273 2015 139 147
257. G. Lauc, and et al. Complex genetic regulation of protein glycosylation Mol. Biosyst. 6 2010 329 335
258. E. Mossner, and et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity Blood 115 2010 4393 4402
259. L.C. James, and et al. 1.9 A structure of the therapeutic antibody CAMPATH-1H Fab in complex with a synthetic peptide antigen J. Mol. Biol. 289 1999 293 301